Top

Published in:

01-02-2008 | Case Report

Polymyalgia rheumatica as the manifestation of unclassified aortitis

Authors: Hiroshi Kataoka, Tatsuya Atsumi, Toko Hashimoto, Tetsuya Horita, Shinsuke Yasuda, Takao Koike

Published in: Modern Rheumatology | Issue 1/2008

Abstract

Polymyalgia rheumatica (PMR) frequently occurs with giant cell arteritis (GCA). We report here two cases of PMR with aortitis in the absence of diminished pulse and manifestations related to GCA. Contrasted CT, MR angiography, and F-18-deoxyglucose positron emission tomography showed aortitis without stenosis that is not classified into any of large vasculitides. It should be acknowledged that aortitis might present as PMR and imaging studies are recommended.

Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol. 2004;18:705–22.PubMedCrossRef

Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129–34.PubMedCrossRef

Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–7.PubMedCrossRef

Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979;38:434–9.PubMedCrossRef

Narvaez J, Narvaez JA, Nolla JM, Sirvent E, Reina D, Valverde J. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology (Oxford). 2005;44:479–83.CrossRef

Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med. 2000;108:246–9.PubMedCrossRef

Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef

Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum. 2003;49:594–8.PubMedCrossRef

Kobayashi Y, Numano F. 3. Takayasu arteritis. Intern Med. 2002;41:44–6.PubMedCrossRef

10.

Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003;139:505–15.PubMed

11.

Gravanis MB. Giant cell arteritis and Takayasu aortitis: morphologic, pathogenetic and etiologic factors. Int J Cardiol. 2000;75 Suppl 1:S21–3.PubMedCrossRef

12.

Iwamoto M, Ogawa-Shirota Y, Sato H, Yoshio T, Okazaki H, Fujita A, et al. Clinical images: early diagnosis of Takayasu arteritis using gadolinium-enhanced magnetic resonance imaging. Arthritis Rheum. 1999;42:1549.PubMed

Title: Polymyalgia rheumatica as the manifestation of unclassified aortitis
Authors: Hiroshi Kataoka
Tatsuya Atsumi
Toko Hashimoto
Tetsuya Horita
Shinsuke Yasuda
Takao Koike
Publication date: 01-02-2008
Publisher: Springer Japan
Published in: Modern Rheumatology / Issue 1/2008
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-007-0019-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Online First publication of Modern Rheumatology

Peripheral CD4+ T cells showing a Th2 phenotype in a patient with Mikulicz's disease associated with lymphadenopathy and pleural effusion

Effect of estrogen replacement therapy on arthritis and bone mineral density in estrogen-replete rats with collagen-induced arthritis

Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations

Interleukin-17 gene expression in patients with rheumatoid arthritis

Multicentric diffuse-type giant cell tumor of the hand

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials